Results from an early safety study of Moderna Inc.’s coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly on par with high-dose flu shots, researchers said.
A Covid-19 vaccine could be broadly rolled out in the United States by the middle of 2021 or a little later, the head of the federal government’s disease control agency said.
To effectively create immunity to Covid-19, we need to educate to vaccinate.
White House Coronavirus Task Force Coordinator Dr. Deborah Birx dismissed the notion that the White House was considering a strategy of allowing Americans to become infected with coronavirus in order to reach “herd immunity.”
Antibody levels against the novel coronavirus rose and then held steady for up to four months in more than 90% of recovered Covid-19 patients in Iceland, according to a published study.
First U.S. novel coronavirus reinfection case identified in Nevada study (Reuters) – Researchers for the first time have identified someone in the United States who was reinfected with the novel […]
Two European patients were confirmed to have been re-infected with the coronavirus, raising concerns about people’s immunity to the virus as the world struggles to tame the pandemic.
Several studies suggest that even mild cases of Covid-19 stimulate lasting immune responses, not only in disease-fighting antibodies, but in B-cells and T-cells.
German biotech company BioNTech and U.S. drugmaker Pfizer said they would begin a pivotal global study to evaluate their lead COVID-19 vaccine candidate.
Recently published scientific studies include research into whether Covid-19 immunity might not be possible.
